Lazabemide

Lazabemide
Clinical data
Routes of; administration	Oral
ATC code	none
Legal status
Legal status	Development terminated;
Identifiers
	IUPAC name N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide;
CAS Number	103878-84-8
PubChem (CID)	71307
IUPHAR/BPS	6640
ChemSpider	64426
UNII	420HD787N9
KEGG	D04681
Chemical and physical data
Formula	C8H10ClN3O
Molar mass	199.64 g/mol

Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.^[1]

References[edit]

^ Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.". J Neural Transm Suppl. 41: 321–325. PMID 7931245.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Clinical data

Routes of administration	Oral
ATC code	none
Legal status
Legal status	Development terminated
Identifiers
IUPAC name N-(2-aminoethyl)-5-chloro-pyridine-2-carboxamide
CAS Number	103878-84-8
PubChem (CID)	71307
IUPHAR/BPS	6640
ChemSpider	64426
UNII	420HD787N9^Y
KEGG	D04681
Chemical and physical data
Formula	C₈H₁₀ClN₃O
Molar mass	199.64 g/mol